Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...

The CEO at the Illinois-based company with operations in Minnesota expects earning to return to a pre-pandemic profit model ...

Robert Ford’s comments come as new CGMs and insulin pumps continue to roll out in the diabetes tech space, including over-the-counter glucose sensors.

Normoglycemic individuals spent 87% of their daily time in in the “tight range” of glucose levels (70-140 mg/dL) and the remainder above 140 mg/dL.

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

In recent years, digital health has become a new development trend in the global health and medical industry. By using ...

DexCom, Inc. (NASDAQ:DXCM) has also consistently beat EPS estimates in the last 4 quarters. The stock has received an average ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...

Not everyone in the health field is so bullish on the prospects of CGMs for everyone, and question whether digging in too ...